Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
第2相
早期終了
NCT06585150
| 対象疾患 | RSV Infection |
|---|
| 相 | 第2相 |
|---|
| スポンサー | Gilead Sciences |
|---|
| ステータス | 早期終了 |
|---|
| 参加者数 | 150 名 |
|---|
| 介入（薬剤） | Obeldesivir, Obeldesivir Placebo |
|---|
| 開始日 | 2024年10月14日 |
|---|
| 完了日 | 2025年5月8日 |
|---|
| 結果公開日 | 2026年6月30日 |
|---|
概要
The goal of this clinical study was to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it was in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers wanted to see if obeldesivir can help participants' symptoms get better faster. The primary objectives of this study were to evaluate the efficacy of ODV in reducing the duration of symptoms and to evaluate the safety and tolerability of ODV in nonhospitalized adult participants with acute RSV infection.
Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Through Day 15
Up to Day 15 · days
| Obeldesivir | 3.2 days |
|---|
| Placebo | 3.9 days |
|---|
| p-value | 0.2005 |
|---|
| Difference in median time | -0.7 |
|---|
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
Up to 5 days plus 30 days · percentage of participants
| Obeldesivir | 13.5 percentage of participants |
|---|
| Placebo | 16.2 percentage of participants |
|---|
Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities
Up to 5 days plus 30 days · percentage of participants
| Obeldesivir | 59.5 percentage of participants |
|---|
| Placebo | 57.5 percentage of participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。